# ADMA Biologics Inc (ADMA) Stock Analysis: A Biotech with 63.74% Potential Upside and Strong Revenue Growth

- Link: https://www.directorstalkinterviews.com/adma-biologics-inc-adma-stock-analysis-a-biotech-with-63-74-potential-upside-and-strong-revenue-growth/4121209662
- Published: 2025-07-28T10:50:05+01:00
- Author: Madison Wilson

Investors with an eye for opportunities in the biotechnology sector should take 
a closer look at ADMA Biologics Inc (ADMA). With an impressive revenue growth rate
of 40.20% and a projected potential upside of 63.74%, this healthcare company is
making waves in the industry. Specializing in the development and commercialization
of plasma-derived biologics, ADMA Biologics is poised for a promising future.

ADMA Biologics operates in the United States and internationally, focusing on the
treatment of immune deficiencies and infectious diseases. Among its notable products
are BIVIGAM and ASCENIV, both intravenous immune globulin (IVIG) products designed
for treating primary humoral immunodeficiency. The company also offers Nabi-HB, 
a treatment for acute exposure to Hepatitis B. Its innovative pipeline further includes
plasma-derived therapeutics aimed at combating S. pneumonia infections.

Currently priced at $18.01, ADMA’s stock has witnessed a 52-week range from $11.30
to $24.51. Despite a modest price change of 0.70 (0.04%), the stock’s average target
price of $29.49 signals a significant upside potential when compared to its current
valuation. Analysts have shown confidence in ADMA, with two buy ratings and one 
hold rating, and no sell ratings.

The company boasts a market cap of $4.3 billion, reflecting its substantial footprint
in the biotechnology sector. While some traditional valuation metrics like P/E and
PEG ratios are unavailable, the forward P/E stands at 18.76, suggesting that the
market expects future earnings growth.

Technically, ADMA’s 50-day moving average of $19.01 and 200-day moving average of
$18.74 indicate stability, although the RSI (14) at 80.86 suggests the stock may
be overbought. Moreover, the MACD of -0.48, with a signal line at -0.53, highlights
potential caution for momentum traders.

ADMA’s financial performance is underscored by a robust EPS of 0.84 and a remarkable
return on equity of 78.45%, further complemented by a free cash flow of over $52
million. Despite not offering a dividend, the company’s reinvestment strategy is
evident in its payout ratio of 0.00%. This approach supports continuous growth and
expansion in its core operations.

As the company continues to expand its pipeline and distribution channels, the potential
for revenue and market share growth remains high. For investors seeking exposure
to the healthcare sector, particularly in biotechnology, ADMA Biologics represents
an intriguing opportunity with its strong growth metrics and considerable upside
potential.

Share on:
